Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +60

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Dividend AI-generated analysis

πŸ“ˆ Gilead's HIV franchise drove strong Q2 performance with product sales excluding Veklury increasing 10% to $7.6 billion.

πŸ’Š Biktarvy sales grew 7% to $3.8 billion while Descovy surged 48% to $967 million in the second quarter.

πŸ”¬ Liver-disease segment revenue increased 10% to $877 million, led by Livdelzi doubling from $78 million to $167 million.

πŸ“‰ Cell Therapy sales declined 14% to $417 million and Yescarta fell 12% amid competitive headwinds.

πŸ’° Gilead raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion and increased the quarterly dividend by 3.8%.

⚠️ The company faces concentration risk as HIV sales account for roughly three-quarters of total product revenue.

πŸ’Έ Acquisitions of Arcellx, Tubulis, and Ouro Medicines resulted in $11.2 billion in acquired in-process R&D expenses.

πŸ“Š GAAP quarterly losses per share reached $8.45 due to acquisition-related charges and non-GAAP losses of $6.75.

Bullish Signals
  • Gilead's HIV franchise continues to gain momentum with product sales excluding Veklury increasing 10% to $7.6 billion in Q2.
  • Key HIV products showed exceptional growth, with Descovy revenue jumping 48% to $967 million and Biktarvy rising 7% to $3.8 billion.
  • The liver-disease segment delivered strong results with sales increasing 10% to $877 million, driven by a doubling in Livdelzi revenue.
  • Management raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion and increased the quarterly dividend by 3.8% to $0.82 per share.
Risk Factors
  • Approximately three-quarters of Gilead's product revenue comes from its HIV franchise, creating significant concentration risk.
  • Cell Therapy sales declined 14% to $417 million and Yescarta fell 12%, indicating uneven performance outside the HIV core business.
Full Analysis
Gilead Sciences (NASDAQ:GILD) reported a strong second quarter driven by its HIV franchise, which generated $5.69 billion in sales, representing roughly three-quarters of total product revenue. Key HIV products showed robust growth, with Biktarvy sales rising 7% to $3.8 billion and Descovy jumping 48% to $967 million. The company also saw significant gains in its liver-disease segment, where Livdelzi revenue more than doubled to $167 million. Beyond HIV, Gilead demonstrated mixed performance outside its core franchise. While Trodelvy sales increased 26% to $457 million, cell therapy revenues declined 14% amid competitive pressures, and Yescarta fell 12%. Despite these variances, the company raised its 2026 product-sales guidance to a range of $30.1 billion-$30.4 billion and increased its quarterly dividend by 3.8% to $0.82 per share starting in 2026. The article highlights Gilead's strategic trade-offs, noting that while it offers stronger current growth momentum, the business carries significant concentration risk due to its heavy reliance on HIV therapies. Additionally, the company recorded substantial one-time charges related to acquisitions of Arcellx, Tubulis, and Ouro Medicines, resulting in GAAP quarterly losses per share of $8.45. These factors position Gilead as a high-growth but concentrated investment compared to more diversified peers.